Higher Expression of CD44 in De Novo Diffuse Large B-cell Lymphoma Than in Richter Syndrome - Université de Lorraine Access content directly
Proceedings Laboratory Investigation Year : 2022

Higher Expression of CD44 in De Novo Diffuse Large B-cell Lymphoma Than in Richter Syndrome

Abstract

Background: A subset of patients with chronic lymphocytic leukemia will experience transformation into Richter syndrome (RS), usually a diffuse large B–cell lymphoma (DLBCL). Clonal relationship based on IGHV analysis can determine a true RS transformation. Separating de novo DLBCL and RS is essential because novo DLBCL have a significantly better prognosis. The aim of this study is to find differentially expressed proteins in RS and de novo DLBCL. Design: The study comprised a total of 44 samples, specifically 18 RS and 26 de novo DLBCL of the non-GCB type. Among the RS, 8 were clonally related, 2 were clonally unrelated and for 8 no information was available regarding the clonal relationship. Initial proteomic screening analysis was processed through liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). Among this 44 samples, 20 (10 RS and 10 de novo DLBCL) were analyzed by immunohistochemistry in order to evaluate the expression of CD44 and PKC-β. H-score was calculated with the semi quantitative evaluation of percentage of positive PKC-β cells multiplied by the weighted intensity of stain. All statistical analyses were performed using Student’s t-test. A p < 0.05 was considered statistically significant. Results: LC-MS/MS proteomic study identified a panel of proteins differentially expressed between RS and de novo DLBCLs (FDR<0.05), including CD44 (which was comparatively underexpressed in RS) and PKC-β (which was comparatively overexpressed in RS). The immunohistochemical study confirmed that CD44 expression is significantly higher in de novo DLBCL than in RS (p<0.002). PKC-β is also overexpressed in RS, but the difference is not significant. Conclusions: RS has a very poor prognosis and should not be confused with de novo DLBCL. This study demonstrated the interest of CD44 to immunophenotically distinguish RS from de novo DLBCL.

Dates and versions

hal-03952983 , version 1 (23-01-2023)

Identifiers

Cite

Charline Moulin, Sébastien Hergalant, Romain Piucco, Romain Morizot, Christine Carapito, et al.. Higher Expression of CD44 in De Novo Diffuse Large B-cell Lymphoma Than in Richter Syndrome: USCAP 2022 Abstracts: Hematopathology (851-976). Laboratory Investigation, 102, pp.942-1088, 2022, ⟨10.1038/s41374-022-00758-y⟩. ⟨hal-03952983⟩
37 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More